Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.19 +5.0%	$4.55	$3.02 ▼ $11.88	$22.68M	-0.74	163,104 shs	131,694 shs
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
FNCH Finch Therapeutics Group	$13.48	$12.77	$10.15 ▼ $15.85	$21.65M	1.19	2,237 shs	66 shs
GNPX GENPREX	$0.17 +17.0%	$0.25	$0.14 ▼ $3.97	$5.63M	-0.53	6.52 million shs	97.22 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	+3.71%	-21.97%	+14.48%	-61.91%
ELEV Elevation Oncology	0.00%	0.00%	0.00%	+15.62%	-54.96%
FNCH Finch Therapeutics Group	0.00%	+6.14%	+7.84%	+3.69%	+22.10%
GNPX GENPREX	0.00%	-20.69%	-41.05%	-38.80%	-76.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CING Cingulate	2.4351 of 5 stars	3.5	3.0	0.0	0.0	2.1	0.8	0.6
ELEV Elevation Oncology	1.3522 of 5 stars	3.0	0.0	0.0	0.0	0.6	1.7	0.6
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	1.5935 of 5 stars	0.0	3.0	0.0	4.7	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	3.00	Buy	$26.25	526.49% Upside
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
GNPX GENPREX	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, FNCH, ELEV, and CING Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$61.00 ➝ $62.00
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$15.55M	-$4.10	0.00	N/A	N/A	N/A	-232.16%	-132.07%	11/6/2025 (Estimated)
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	11/4/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-809.27%	-386.95%	11/11/2025 (Estimated)

Latest GNPX, FNCH, ELEV, and CING Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	CING Cingulate	-$0.82	-$1.09	-$0.27	-$1.09	N/A	N/A
8/14/2025	Q2 2025	GNPX GENPREX	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	1.52	1.52
ELEV Elevation Oncology	0.67	19.40	19.40
FNCH Finch Therapeutics Group	N/A	3.87	3.87
GNPX GENPREX	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
ELEV Elevation Oncology	83.70%
FNCH Finch Therapeutics Group	21.77%
GNPX GENPREX	14.05%

Insider Ownership

Company	Insider Ownership
CING Cingulate	4.04%
ELEV Elevation Oncology	8.10%
FNCH Finch Therapeutics Group	44.90%
GNPX GENPREX	0.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	20	5.41 million	5.19 million	Not Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
GNPX GENPREX	20	33.47 million	33.32 million	No Data

GNPX, FNCH, ELEV, and CING Headlines

Recent News About These Companies

Genprex receives notice of allowance for multiple patents for Reqorsa

August 18, 2025 | msn.com

Genprex Secures Patent Allowances for Gene Therapy

August 18, 2025 | tipranks.com

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

August 18, 2025 | prnewswire.com

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

August 4, 2025 | prnewswire.com

Genprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Genprex reports positive results from diabetes gene therapy study

June 25, 2025 | investing.com

Genprex Announces Positive Preclinical Results for GPX-002

June 24, 2025 | tipranks.com

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

June 24, 2025 | prnewswire.com

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

June 23, 2025 | prnewswire.com

Genprex to Participate at BIO 2025 International Convention

June 3, 2025 | prnewswire.com

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025 | prnewswire.com

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025 | prnewswire.com

Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes

May 9, 2025 | bioworld.comB

Genprex inks sponsored research agreement with the University of Pittsburgh to study diabetes gene therapy in Type 1 and Type 2 diabetes

May 8, 2025 | pharmabiz.comP

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025 | prnewswire.com

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025 | prnewswire.com

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

April 30, 2025 | prnewswire.com

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

April 29, 2025 | prnewswire.com

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

April 28, 2025 | prnewswire.com

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

April 24, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNPX, FNCH, ELEV, and CING Company Descriptions

Cingulate NASDAQ:CING

$4.19 +0.20 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.03 -0.16 (-3.82%)

As of 08/22/2025 07:28 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Finch Therapeutics Group NASDAQ:FNCH

$13.48 0.00 (0.00%)

As of 08/22/2025

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

GENPREX NASDAQ:GNPX

$0.17 +0.02 (+17.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.17 +0.00 (+2.20%)

As of 08/22/2025 07:59 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time